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SUMMARY
The ability of insulin-like growth factor (IGF) to induce growth in hypophysec-
tomized immature rats was tested by continuous infusion of the partially purified
factor at daily doses of 6, 21, and 46 mU for an 8-day period. A dose-dependent
growth of the proximal epiphyseal cartilage of the tibia and an associated stimula-
tion of the primary spongiosa were produced by these amounts of IGF. The two highest
doses of IGF also resulted in dose-dependent increases of body weight. Gel permea-
tion of the sera at neutrality showed that the large-molecular-weight IGF binding
protein was not induced by the infusion of IGF, whereas it was generated in the sera
of hypophysectomized rats that had been infused with daily doses of 86 mU of human
growth hormone.
INTRODUCTION
According to the somatomedin hypothesis (ref. 1), longitudinal body growth is
stimulated by the direct action of somatomedin on epiphyseal chondrocytes. The plasma
concentrations of somatomedin or insulin-like growth factors and their binding pro-
teins are regulated by pituitary growth hormone (refs. 2 and 3). Although there is
a considerable body of evidence from in vitro studies that supports the somatomedin
hypothesis (refs. 4 and 5), the demonstration of growth stimulation in the whole
animal by somatomedin pep tides has been lacking until recently. Using Snell dwarf
mice, van Buul-Offers and Van den Brande (ref. 6) showed that longitudinal skeletal
growth and body weight gain could be stimulated by the injection of a somatomedin
preparation for 4 weeks. It is reported herewith that immature hypophysectomized
rats, infused with insulin-like growth factor (IGF), show body weight gains and epi-
physeal cartilage proliferations similar to that produced by pituitary growth hormone.
MATERIALSANDMETHODS
Male albino rats weighing between 85 and 95 g were hypophysectomized and checked
for weight gain during the ensuing 2- to 3-week period. Rats that gained not more
than 0.5 g/day were considered completely hypophysectomized and were selected for
assay. Testicular weights at autopsy ranged between 150 and 200 mg and served to
confirm the completeness of hypophysectomy. The rats had free access to commercial
rat chow (Altromin, Lage, Fed. Rep. Germany) and water and were maintained on a
12-hr light and dark cycle.
The partially purified preparation of IGF used in these studies has a specific
activity of 13 mD of insulin equivalents per milligram, as standardized with the fat
pad assay of Froesch et al. (ref. 7). It had been processed through the Sephadex gel
filtration steps in the purification scheme devised by Rinderknecht and Humbel
(ref. 8). The content of the imrnunoreactiveIGF I,and II.in_the 13 mU/mg prepara-
tion as determined in this laboratory was~73% and ~27%,respectively.
Clinical grade human growth hormone (hGH) ~as purchased from Leo Pharmaceuticals
(Denmark). The preparation was dissolved in sterile saline, loaded into Alzet mini-
pumps of 240 ~£ capacity (No. 2001) (Alza, Palo Alto, California) and, after 2 to
3 hr soaking in sterile saline, were implanted subcutaneously into hypophysectomized
rats under light ether anaesthesia. The.minipumps were rated to deliver 1 ~£/hr.
The IGF preparation was administered at three different concentrations, namely, 46,
21, and 6 mU/day from minipumps containing, respectively, 35, 16.3, and 4.8 mg of the
IGF preparation per pump. Human GH was infused at the rate of 86 mU/day. The rats
were sacrificed on the ninth day after implantation and the pumps dismantled to con-
firm that the contents had been delivered. The tibia was removed and stained accord-
ing to the method of Evans et al. (ref. 9). In addition, the testes, thymus, liver,
soleus muscle, and the retroperitoneal and epididymal fat pads were dissected and
weighed. The significances of means were evaluated by the Student's t-test.
Blood samples were drawn at autopsy from the abdominal aorta of the rats under
ether anaesthesia and the serum was used for the determination of the IGF binding
protein pattern according to the radiochromatographic method of Kaufmann et al.
(ref. 2) modified for in vitro use. Whereas these authors injected the IGF tracer
intravenously into the rats and chromatographed the serum 20 min after the injection,
in the present study the tracer was added directly to the rat serum, equilibrated for
24 hr at 4°C, and then applied to Sephadex G-200 columns at neutral pH as given in
the legend to figure 4. This procedure yields a binding pattern that, quantitatively,
is slightly different from that obtained after the in vivo administration of the IGF
tracer with respect to the relative heights of the radioactive peaks II and III -
peak III being higher than peak II for normal serum and for serum from the hypophysec-
tomized rats treated with GH. However, qualitatively, the binding patterns obtained
from the present study are similar to those reported earlier by Kaufmann et al.
(ref. 2) and more recently, by Moses et al. (ref. 3).
RESULTS
The body weight changes associated with the infusion of 21 and 46 mU of IGF per
day for 8 days are shown in figure 1. A dose of 6 mD of IGF produced no increase in
body weight, although small but significant increases in epiphyseal cartilage width
were consistently detectable, as noted below. A noteworthy feature of the IGF
effects is that no weight gain occurred during the first 2 days of infusion. This
contrasts with the immediate weight gain effected by the hGH infusion. The reason
for this difference is not apparent at this time. It appears from these curves that
the rate of weight gain induced by the infusion of IGF at the rate of 46 mD nearly
equals that given by 86 mU of hGH, but the maximal response was smaller.
From the standpoint of epiphyseal response, the infusion of 6 mU of IGF per day
appears to be the minimal effective 40se for eliciting a significant response (20%,
P < 0.05 vs control). The lack of a body~eight gain at this dose is not unexpected
in view of the lower sensitivity of body weight responses compared to that of the epi-
physeal cartilage. When the dose of infused IGF was increased to 21 mD/day, the epi-
physeal cartilage response increased to 39% of control, corresponding to a body weight
increase of4 g; when the dose was increased to 48 mD/day, the cartilage response
increased to 50% of control, corresponding ~o a body weight increase of 12 g. A log
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dose-response relationship for the epiphyseal cartilage response is shown in fig-
ure 2. The marked proliferation of the epiphyseal cartilage plate after treatment
with the high dose of IGF is shown in the silver-stained section of the tibias from
treated and control rats (fig. 3). It is evident that the zone of provisional calci-
fication and the primary spongiosa were stimulated by IGF in a manner very similar
to that produced by growth hormone.
The highest dose of IGF also produced a significant increase in the wet weights
of the liver, thymus, and soleus muscle (table 1). In this respect the IGF resembled
the response given by growth hormone. If the weight of these organs was expressed
as a percentage of body weight, then the values were not significantly different,
indicating that the organ weights increased in proportion to the body weight. IGF
decreased the absolute weights of the epididymal fat pads although the change at the
highest dose was not significant due to the small number of animals. When calculated
relative to 100 g body weight, the epididymal fat pads lost 50% of their weight
(p < 0.01) at the highest dose of IGF. These reductions in epididymal fat pad weight
are unexpected in the light of the antilipolytic action of IGF and requires investi-
gation with pure IGF.
Since sera from hypophysectomized rats have been found to be deficient in high
molecular weight binding protein that can be restored by treatment with growth hor-
mone (refs. 2 and 3), it was considered of interest to determine whether IGF infusion
could also repair the deficiency. For this purpose, pooled sera injected with the
high dose of IGF was submitted to radiochromatographic analysis on G-200 following
the in vitro incubation of the sera with 125 I - 1abe 1ed IGF for 24 hr at 4°C. In fig-
ure 4 is shown a comparison of the elution profiles of the labeled peaks from the
sera of normal rats and of hypophysectomized rats treated with IGF or hGH, or with
human serum albumin as control. Normal serum displayed five peaks of radioactivity
in the elution profile: I, nonspecifical1y bound IGF; II and III, the labeled IGF
that bound specifically to a large molecular weight region (~200,000) and to a lower
molecular weight region, respectively; peak IV represented free labeled IGF, whereas
peak V at 100% of the bed volume contained free iodine and iodinated degradation
products of IGF. As shown in figure 4, in the presence of an excess of cold IGF
(1 mU) the binding to peaks II and III was practically abolished, whereas the activity
in peak IV was drastically increased by the displacement of labeled IGF from the
peaks with specific binding.
In contrast to the serum pattern from normal rats, the pattern from untreated
hypophysectomized rats revealed only four peaks of radioactivity, peak II being
absent. Infusion of hGH (86 mU/day for 8 days) restored the binding in peak II.
However, infusion of the high dose of IGF (46 mU/day for 8 days) did not repair the
deficiency in peak II (fig. 4) despite a significant body weight gain and epiphyseal
response.
DISCUSSION
The present data demonstrate that hypophysectomized rats can grow in response
to a continuously administered preparation of a crude IGF prepared from human plasma.
In view of the low purity of this preparation (13 mU/mg as compared to 330 mU/mg for
pure IGF I) as well as the presence of both types of IGF, these experiments need
to be repeated with pure IGF I and II. With regard to the possibility that contami-
nants such as insulin or thyroxin may have elicited the observed responses, it should
be noted that these hormones do not stimulate dose-dependent growth in the
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hypophysectomized rat. Although in the Snell dwarf mouse thyroxin does stimulate
body weight gain and increase in skeletal length, in hypophysectomized rats its
effect on growth is to synergize the action of pituitary growth hormone (ref. 10).
The effects of pure IGF I were reported by Schoenle et al. (ref. 11) while the pres-
ent manuscript was in revision. Their results showed that the infusion of the highly
purified peptide stimulated epiphyseal cartilage growth, body weight gain, and
H3-thymidine incorporation into rib cartilage of hypophysectomized rats. These
results taken together indicate that the growth promoting effects obtained with
crude IGF can be duplicated with essentially the equivalent unit age of pure IGF I,
that is, the infusion of IGF on the order of 15 to 50 mU (fat pad assay) per day
per 100 g body weight.
Since the present preparation is a mixture of IGF I and II, administration of·
the pure IGF types individually will be required to ascertain whether both hormones
given alone elicit the same qualitative as well as quantitative growth responses
in vivo. In this regard it may be noted that in several in vitro systems (chick
embryo fibroblasts, chick cartilage, human embryonic lung fibroblasts, and human
adult fibroblasts) the response to the two growth factors is similar (refs. 12
through 14), whereas in others (rat cartilage and calvarian cells) (Schmid and
Froesch, in preparation) IGF I is more potent than IGF II. Also, disorders of growth
hormone secretion are reflected more markedly by changes of the plasma concentrations
of IGF I than of IGF II (ref. 15).
A growth response of Snell dwarf mice to a partially purified preparation of
somatomedin, quantified by radioimmunoassay for the content of other hormonally active
contaminants, has been reported by van Buul-Offers and Van den Brande (ref. 6). They
injected 6 units of activity (porcine cartilage assay) for 4 weeks and obtained a
significant increase in body length and weight comparable to that obtained with 8.3 ug
of hGH or with 0.1 ug/day of thyroxin. A dose dependency of growth rate on somato-
medin dose was not tested. Holder et al. (ref. 16) also reported a significant body
weight gain after treating dwarf mice with somatomedin for 10 days; however, bone
growth as measured by tail, femur, and tibia lengths was not significantly increased,
perhaps because of the shorter time of injection as compared to that of
van Buul-Offers.
It is of interest to compare the doses of IGF used in the hypophysectomized rats
with those reported for Snell dwarf mice. If the doses of somatomedin administered
are calculated per 100 g of body weight by means of the relationship that 1 costal
cartilage somatomedin unit in 1 ml of pooled human plasma is equivalent to 0.2 mll of
IGF'by the fat pad assay (refs. 17 and 18), then the doses of activity expressed as
IGF per day per 100 g body weight are the same order of magnitude in the different
studies, namely, van Buul-Offers, 12 mU; Holder, 13 mU; Schoenle, 14-28 mll; this
paper, 21-46 mU. From these values it would appear that roughly the same doses of
IGF activity produce a significant body weight gain in hypophysectomized rats as in
Snell dwarf mice.
In view of the ability of unfractioned human plasma or serum (ref. 19) to pro-
duce a growth response in hypophysectomized rats, the question arises as to how much
of this response is accountable by the content of IGF in plasma or serum. In tibial
assays of pooled human plasma, a 40% increase in epiphyseal cartilage width was
achieved in 4 days by the daily injection of 9 ml of plasma (0.2 mU IGF per ml) for
4 days, or a total of about 10 mU of IGF. In the present work, however, a daily
dose of 21 mU of IGF for 8 days, or a total of 168 mU, was required to achieve the
40% increase. The l7-fold higher ratio of growth promoting activity in plasma rela-
tive to its IGF content suggests that IGF alone cannot account for the entire growth
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promoting activity of plasma. This would indicate that other plasma factors such as
the IGF carrier protein, platelet-dependent growth factors (ref. 20), and fibroblast
growth factor (ref. 21) may be needed to augment or synergize the response to IGF.
An additional finding of interest is that IGF, in contrast to GH (refs. 2 and 3),
does not induce formation of the large molecular weight IGF carrier protein in serum
(fig. 4). The carrier protein binds most of the IGF present in serum (ref. 22) and
is likely to be responsible for the long half-life of IGF (ref. 23). IGF injected
intravenously as a bolus causes a profound hypoglycemia that is readily demonstrable
in adrenalectomized rats (ref. 24). In the absence of the carrier protein, the slow
continuous subcutaneous infusion by means of the A1zet pumps appears to have deliv-
ered enough IGF to the cells responsible for growth but not enough to stimulate the
insulin target tissues. It is possible that the IGF-mediated aspects of growth hor-
mone action cannot be completely mimicked with the free IGF peptide because the hypo-
physectomized animal lacks the large molecular weight binding protein.
In summary, it has been shown that IGF has significant growth promoting effects
in pituitary deficient rats thereby providing direct evidence in favor of the soma-
tomedin concept, as originally formulated by Daughaday et a1. (ref. 1).
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TABLE1.- ORGANANDBODYWEIGHTSAT AUTOPSY
Fat pads
Daily Body weight Liver, Thymus, Soleus, Testes,Treatment dose Epididymal, Retro-l'>g mg mg peritoneal, mg mgg
mg
mg
Control (5)a 0 91.4 0 3.83 ±0.20 258 ±24 280 ±33 193 ±48 166 ±6
hGH (4 ) 86 113.8 17 ±0.9 b 5.27 ±0.31 b 386 ±47c 245 ±41 188 ±32 191 ±21
IGF (5) 21 97 4.2 ±1.6 4.37 ±0.10 332 ±25 234 ±23c 156 ±30 198 ±23
Control (3) 0 91 0 3.50 ±0.30 172 ±34 281 ±58 124 ±23 41 ±2.0 206 ±17
IGF (3) 46 115 11. 7 ±2.8 b 4.68 ±0.25 c 278 ±9c 183 ±26 97 ±44 53 ±2.8 c 130d
Control (3) 0 103 8 ±1.0 4.38 ±0.25 268 ±13 45 ±3.2 168 ±9.5
hGH (4 ) 48 121 23 ±2.2 b 5.33 ±0.43 507 ±57 255 ±26 56 ±3.0 e 194 ±15
IGF (4) 6 100 2.3 ±l.O 4.27 ±0.5 299 ±42 183 ±30c 43 ±3.2 150 ±16
aNumber of rats per group given in parentheses.
b p < O.Ol.
~p < 0.05.
dFrom two rats.
ep < O.l.
Values presented are means ± standard errors.
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Figure 1.- Increases in the body weight of hypophysectomized rats infused for 8 days
with IGF at the rate of either 21 or 46 mD/day and hGH at the rate of 86 mD; con-
trol rats were infused with an equal weight of human serum albumin. There were
four or five rats per group except for highest dose IGY group which contained
three rats.
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Figure 2.- Response of epiphyseal cartilage width to the log of the dose of IGE infused per day for 8 days.
Response expressed as percentage increase of control rats infused with human serum albumin. The infusion
of 86 mD of hGH increased the cartilage width by 100%.
Control
IGF-treated
hGH-treated
Fig u re 3 . - Proxima l e p i physeal car tilage from hyp oph y s e ct omi z ed r ats s ho wi ng s ti mula-
ti on of ca r t i lage gr owth a n d calcif ica t io n in z one s o f p r ovisi on al ca lcif ica t io n
a n d prim a ry spongi os a. Contr o l s wer e in fu s ed with human s erum a l b umi n, I GF t r e at ed
with 21 mU/d ay, a n d hGH tr e at ed with 86 mU/d ay; st ain ed with 1% s i l ve r nitr at e
a c co r d i ng to r eference 9.
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Figure 4.- Distribution of 125 l - 1abe 1e d lGF I in effluent fractions obtained by gel
permeation of rat sera on Sephadex G-200 at pH 7.4; 125 l _I GF I (7.8 x10 G cpm) was
equilibrated for 24 hr at 4°c in 0.25 ml of Dulbecco's buffer, pH 7.4 and 0.25 ml
of pooled sera (three rats) from the following groups of hypophysectomized rats:
IGF-hypox, infused with 46 mD of lGF per day for 8 days; GH-hypox infused with·
86 mD of hGH for 8 days; hypox, infused with saline containing human serum albumin
equivalent to the weight of lGF, for 8 days. The mixture was then applied to a
Sephadex G-200 column (2 x60 em, bed volume 190 ml) equilibrated with Du1becco's
buffer, pH 7.4; 2.2 ml fractions were collected and counted in a liquid scintilla-
tion counter.
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